Answers are grounded in this paper and cite their sources.
Background Whole-brain radiotherapy (WBRT) provides intracranial disease control but is associated with neurocognitive toxicity. Following stereotactic radiosurgery (SRS), selected intracranial recurrences may be managed with further focal treatment rather than immediate WBRT. We evaluated recurrence patterns, salvage treatment, and subsequent WBRT use in a prospective SRS/stereotactic radiotherapy (SRT) cohort. Methods Adults with brain metastases treated under a prospective institutional SRS/SRT protocol were included. Of 298 patients, 269 had received neither prior WBRT nor WBRT as part of index treatment and formed the primary cohort. Intracranial recurrence, salvage-treatment sequence, and radiation necrosis (RN) were recorded. Cumulative incidence of salvage WBRT and overall RN was estimated with death as a competing event; WBRT-free survival, defined as time to salvage WBRT or death, was estimated using Kaplan–Meier analysis. Results Median follow-up was 12.8 months. Intracranial recurrence occurred in 110 of 269 patients (40.9%). Repeat SRS/SRT was first salvage in 47 patients, of whom six subsequently received WBRT. Overall, 34 patients (12.6%) received salvage WBRT. WBRT was selected as first salvage in 30.8%, 10.4%, and 38.8% of patients with isolated in-field, isolated out-of-field, and combined recurrence, respectively (p = 0.005). With death as a competing event, cumulative incidence of salvage WBRT was 3.1%, 8.3%, and 13.2% at 6, 12, and 24 months. Subsequent WBRT incidence after repeat SRS/SRT was 9.5% at 6 months and 12.1% at 12 months. Median WBRT-free survival was 14.6 months (95% CI, 11.7–17.4). Symptomatic RN occurred in 21 patients (7.8%); the 24-month cumulative incidence of overall RN was 10.2%. Conclusions Following initial SRS/SRT, intracranial tumour control was observed in 59.1% of patients, and 87.4% remained free from WBRT at their last recorded follow-up. Among selected patients receiving repeat SRS/SRT as first salvage, 87.2% (41/47) had no subsequent WBRT during available follow-up. These findings support continued focal intracranial management in selected patients, with potential neurocognitive benefits from limiting WBRT-associated toxicity.
No takes yet. Share an insight, caveat, or question.
Madan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: